Skip to main content
OpenTrials
Completed

NCT Number: NCT06385899

Effect of Intensive Monitoring of Patients With Poorly Controlled Type 2 Diabetes With Different Glycemic Background

In Turkey, only 55% of patients with type 2 diabetes have been diagnosed, and 91% of these patients have been receiving treatment. The rate of patients reaching the treatment target is 50%. The pandemic has also affected diabetic patients. It is aimed to determine the characteristics of patients with type 2 diabetes (HbA1c >=10) with poor metabolic control and to evaluate the extent to which metabolic control can be achieved in 12 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Istanbul Goztepe Prof. Dr. Suleyman Yalcin City Hospital

Istanbul, Turkey (Türkiye)

About this study

Patients who applied to Istanbul Medeniyet University Goztepe Prof. Dr. Suleyman Yalcin City Hospital Diabetes Polyclinics and have an HbA1c levels of >= 10% in their examinations will be admitted to the study. Detailed history, including medication usage and previous blood tests will be questioned. The patients will be asked to complete questionnaires about their eating patterns (mindful eating questionnaire), their physical activities (General practice physical activity questionnaire), and whether the participants have depression (Beck depression questionnaire). Anthropometric measurements will be taken, and biochemical data will be recorded. Patients will be grouped according to their previous HbA1c values as a) newly diagnosed, b) those whose diabetes was previously controlled, c) those whose diabetes was previously not at the target range but now worsened, and d) those whose diabetes was poorly controlled from the beginning. Diabetes follow-up will be continued by their respective physicians. The patients will be called again three months after their enrollment to record the most recent biochemical data. Patient characteristics (age, gender, educational status, depression status, eating awareness, exercise characteristics) will be evaluated in accordance with the predetermined HbA1c groups. Again, according to the patient groups, the difference in HbA1c after three months, the frequency of reaching the target, and possible factors associated with the findings will be evaluated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosed with type 2 diabetes
  • give consent to the study
  • accessibility to the previous and recent test results

Exclusion criteria

  • acute infection or inflammation lasting more than a week
  • acute metabolic decompensation
  • unable to attend to the follow-ups
  • having non-thyroid endocrine diseases
  • active oncologic treatment

Treatment and study plan

Primary outcomes

  1. Changes in HbA1c levels after 12 months treatment

    Time frame: twelve months

    Changes in HbA1c levels after 12 months treatment according to the predetermined HbA1c groups.

  2. percentage of patients who reached the HbA1c target of equal to or below 7%

    Time frame: twelve months

    Comparison of the patient groups in their success in reaching the HbA1c target of equal to or below 7%

Secondary outcomes

  1. The effect of education on the HbA1c changes

    Time frame: twelve months

    Educational status may have an impact on HbA1c reduction. Participants who have reached the HbA1c target are compared in terms of their educational level and those who have not.

  2. The effect of depression on the HbA1c changes

    Time frame: twelve months

    The Beck Depression Index will be used to compare participants who reach the HbA1c target and those who do not

  3. The effect of the level of physical activity on the HbA1c changes

    Time frame: twelve months

    Physical activity is graded into 4 levels. Levels will be compared in participants who reach target HbA1c level and who do not

  4. The effect of weight loss on the HbA1c changes

    Time frame: twelve months

    The effect of weight loss on reaching HbA1c target of 7% will be compared

Sponsors and collaborators

Lead sponsor

Goztepe Prof Dr Suleyman Yalcın City Hospital

Other

Registry information

Official study title

The Effect of Close and Intensive Therapeutic Monitoring of Patients With Poorly Controlled Type 2 Diabetes With Different Glycemic Background

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Apr 26, 2024
Registry last updated
Apr 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.